Breaking Finance News

FBR & Co. disclosed Novavax (NASDAQ:NVAX), bumping down its stock price target to $12.00 earlier today

Just yesterday Novavax (NASDAQ:NVAX) traded 0.36% higher at $1.40. NVAX’s 50-day average is $7.35 and its two hundred day moving average is $6.24. With the last stock price down 33.70% from the two hundred day moving average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Trade volume was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares..

Indicating a possible upside of 7.57%, FBR & Co. lowered the target stock price of Novavax (NASDAQ:NVAX) to $12

Previously on 8/23/2016, Vetr Inc. released a statement on Novavax(NASDAQ:NVAX) raised the target price from $0.00 to $8.66 that suggested an upside of 0.17%.

See Chart Below:


Also covering Novavax’s stock price target, a total of 8 equity analysts have issued a report on Novavax. The 12-month target stock price is $15.39 with five firms rating the company a strong buy, three analysts rating the stock a buy, 0 firms rating the stock a hold, 0 rating the stock to underperform, and finally 0 firms rating the stock as sell.

With a market capitalization of $0.0, Novavax has a one-year low of $4.08 and a 52 week high of $10.70 with a P/E ratio of 0.

Brief Synopsis About Novavax (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *